Jim Cramer Highlights Moderna and Merck as Trial-Result Readthrough Lifts Shares in August

Moderna and Merck & Co. entered August with investors hungry for clinical catalysts, and by the end of the month the stocks had posted outsized gains, drawing renewed attention from TV personality Jim Cramer. In a Yahoo Finance market recap, Cramer was cited as calling trial results involving the two companies “encouraging,” a framing that the article links to strong late-month share performance.

Merck’s stock reportedly closed August up 12.6% on the month, while Moderna’s shares closed August up 176%, according to the same Yahoo Finance write-up. The magnitude of Moderna’s rise, far larger than Merck’s, underscored how quickly sentiment can change when markets believe data could improve the commercial outlook for a biopharma program.

The Yahoo Finance piece presented the two companies together, suggesting that investors interpreted their respective trial updates as announcement that product potential may be improving. The article, however, did not spell out in the information provided here which specific trials were referenced, what endpoints were achieved, or whether the results were from early-stage studies or later, pivotal development work.

Moderna, known for using messenger RNA (mRNA) technology, has built much of its growth narrative around the idea that its platform can be adapted to multiple diseases and treatment areas. When markets react strongly to trial readouts, it often reflects expectations that regulators could eventually recognize clinical benefit, and that product demand could follow if approvals land on a favorable timeline.

Merck, by contrast, is a diversified pharmaceutical company whose portfolio includes oncology medicines, vaccines, and immunology products. For large-cap pharma names like Merck, “encouraging” trial commentary from prominent market figures can still move shares, particularly when it comes on top of already-held positions and expectations for pipeline progress.

There is also a limitation to what can be concluded from the Yahoo Finance recap alone. It attributes the upbeat tone to Cramer and connects that tone to August’s stock moves, but the post does not provide detailed trial methodology, numerical results, or forward-looking guidance. As a result, readers should treat the linkage as sentiment-driven rather than a complete description of the underlying scientific evidence.

What to watch next, if the market theme is sustained, is whether further disclosures clarify the scope and strength of the cited trial results, including key endpoints, durability, and any planned next steps in development. For Moderna in particular, investors will likely look for additional data that can support valuation after a very large single-month move, while Merck’s next catalyst calendar will matter for whether its more moderate August increase was the start of a broader trend or a one-off reaction.